Professor Stefano Perlini
University of Pavia, Pavia (Italy)
Member of:
/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
The correct diagnosis in this case, and why
Event: ESC Congress 2023
Topic: Cardiac Amyloidosis
Session: Diagnosing cardiac amyloidosis - a puzzling case study
Case presentation, panel discussion, and audience questions
Event: ESC Congress 2023
Topic: Cardiac Amyloidosis
Session: Diagnosing cardiac amyloidosis - a puzzling case study
Expert perspectives on red flags for ATTR-CM: a practical approach
Event: Heart Failure 2023
Topic: Myocardial Disease
Session: Heart failure and ATTR-CM: recognizing an underdiagnosed condition
Panel discussion
Event: Heart Failure 2023
Topic: Cardiovascular Disease in Special Populations
Session: Improving the diagnosis and treatment of advanced AL amyloidosis with cardiac dysfunction
Emerging therapies in advanced AL amyloidosis with cardiac involvement
Event: Heart Failure 2023
Topic: Cardiovascular Disease in Special Populations
Session: Improving the diagnosis and treatment of advanced AL amyloidosis with cardiac dysfunction
Left ventricular (LV) geometry in severe post-ischemic LV dysfunction: the effect of remote area extracellular matrix remodeling
Event: ESC Congress 2017
Topic: Post infarction period
Session: Acute coronary syndromes
Hypertensive crises treatment in the real-world: are anti-anxiety drugs effective anti-hypertensive agents?
Event: ESC Congress 2016
Topic: Treatment of hypertension
Session: Hypertension in special conditions
Higher prevalence of hypertension in the migrant population in Italy: data derived from the 2012 and 2013 world kidney day
Event: ESC Congress 2016
Topic: Guidelines and implementation in low resource settings
Session: Cardiomyopathy with preserved ejection fraction: Amyloidosis and hypertension
Cardiac mutated transthyretin amyloidosis (m-ATTR): genotype-phenotype correlations
Event: ESC Congress 2016
Topic: Cardiomyopathies
Session: Cardiomyopathies
Myocardiac contraction fraction stratifies prognosis in HFpEF caused by AL of m-ATTR cardiac amyloidosis
Event: HEART FAILURE 2016
Topic: HFpEF - Heart failure with preserved ejection fraction
Session: HFpEF - Heart failure with preserved ejection fraction
ESC 365 is supported by
